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Abstract 
A robust measure of the size of the latent HIV reservoir is essential to quantifying the effect of interventions designed 
to deplete the pool of reactivatable, replication competent proviruses. In addition to the ability to measure a biologi-
cally relevant parameter, any assay designed to be used in a clinical trial needs to be reproducible and scalable. The 
need to quantify the number of resting CD4+ T cells capable of releasing infectious virus has led to the development 
of the quantitative viral outgrowth assay (VOA). The assay as originally described has a number of features that limit 
its scalability for use in clinical trials; however recent developments reducing the time and manpower requirements 
of the assay, while importantly improving reproducibility mean that it is becoming much more practical for it to enter 
into more widespread use. This review describes the background to VOA development and the practical issues that 
they present in utilising them in clinical trials. It describes the innovations that have made their usage more practical 
and the limitations that still exist.
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Background
Development of the VOA
The possibility of a reservoir of latently infected CD4+ T 
cells harbouring proviral DNA but not producing virus 
was identified in early clinical studies on peripheral blood 
from HIV infected persons [1]. When antiretroviral ther-
apy later transformed the prognosis for people living with 
infection it became clear that this reservoir of latently 
infected cells would be a major barrier to eradicating the 
virus. The number of resting CD4+ T cells harbouring 
replication competent viruses has been considered the 
most accurate measure of the latent pool as it is thought 
that these cells are the source of the virus which rebounds 
after cessation of antiviral therapy [2, 3]. The demonstra-
tion that a population of CD4+ HLA-DR- T cells from 
patients on effective treatment could be made to release 
virus upon stimulation with phytohaemagglutinin (PHA) 
led to efforts to quantify the latent reservoir [4–6]. These 
studies established the principle of quantitation by seed-
ing resting CD4+ T cells in limiting dilution before 
activating the cells with a combination of PHA and irra-
diated allogeneic peripheral blood mononuclear cells 
(PBMCs). Due to the low frequency of latently infected 
cells it was necessary to obtain a large volume blood sam-
ple (approximately 200 ml) from study participants.
The amount of HIV Gag protein released by reacti-
vating a single latently infected cell is below the limit of 
detection of a standard p24 ELISA. Therefore the released 
virus is amplified by co-culture with permissive cells. In 
the original assay the cells were co-cultured with PHA 
stimulated, CD8-depleted PBMCs from an HIV-negative 
donor. Maximum likelihood statistics became the stand-
ard to estimate the frequency of latently infected resting 
CD4+ T cells, expressed as infectious units per million 
cells (IUPM) [7].
The use of allogeneic CD8-depleted PBMCs to amplify 
outgrowth virus has biological and practical limitations. 
PBMCs from different donors are not equally permissive 
for HIV infection, leading to different readouts depend-
ing on the PBMC donor. This problem is particularly 
acute when amplifying R5 tropic virus as expression lev-
els of CCR5 vary widely between donors, CXCR4 on the 
other hand tends to be highly expressed making detec-
tion of X4 tropic virus less problematic. One solution 
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is pre-screening of donor PBMCs for CCR5 expression 
level and selecting for high CCR5-expressing donors 
only. Another option is using cells from matched donor-
patient pairs that are shown in  vitro to exhibit robust 
viral replication, a method that also requires extensive 
pre-screening prior to the actual assay [8]. Although 
donor matching reduces inter assay variability for sam-
ples obtained from the same HIV-positive donor, it 
makes the procedure more labour intensive; and together 
with the need to perform leukapheresis to obtain suffi-
cient latently infected cells, makes it harder for VOA to 
scale up to meet the needs of a clinical trial.
Developments of VOA for clinical trial use
Novel VOA
A number of modifications have been introduced to 
improve the original viral outgrowth assay. Two new 
methods utilise cell lines engineered to express high 
levels of CCR5 [9, 10]. These cell line based assays have 
been shown to give IUPM readings similar to PBMC 
based assays [9, 10] and to give highly consistent results 
when sampling the same patient repeatedly [10]. Cell line 
based systems are also less labour intensive as the cells 
do not have to be freshly prepared from blood and stimu-
lated with PHA for each assay. One assay uses a custom 
antibody cocktail to purify resting CD4+ T cells from 
PBMCs of HIV positive donors in a single step, signifi-
cantly reducing processing time from approximately 2 h 
to 45 min [10], a huge advantage when scaling up assay 
numbers for clinical trials. Another recent modification 
proposed to reduce the work required for each assay is 
stimulating the resting CD4+ T cells with CD3/CD28 
microbeads rather than PHA and irradiated allogeneic 
PBMCs. Although the results correlated well with those 
derived from the standard stimulus, the microbead based 
method appeared to be less sensitive [11].
Read‑outs
Recently a number of strategies have been proposed for 
optimising the outgrowth assay by improving the sen-
sitivity of the detection system or simplifying the read-
out. Besides substituting the PBMC based co-culture 
with a CD4/CXCR4/CCR5 expressing clonal cell line, 
we recently reported that the observation of viral cyto-
pathic effect in these cells showed a near-perfect correla-
tion with the detection of p24 from infected cells (Fig. 1) 
[10], further simplifying the assay. Alternatively, use of a 
more sensitive PCR based detection method instead of 
the p24 ELISA can reduce the co-culture time required 
to detect replication-competent HIV [9]. The TILDA 
assay [12] utilises the detection of an increase in multiply 
spliced HIV RNA in CD4+ T cells after stimulation. Sim-
ilar to the VOA, the cells are seeded in limiting dilution 
to obtain a quantitative measure. It uses total rather than 
resting CD4+ T cells, which has the advantage of requir-
ing a smaller blood volume than a VOA and it does not 
need an extended period of culture for detection, how-
ever this means that it measures the inducible reservoir 
in a population of cells different to that used in the VOA. 
Another new assay, TZA, utilizes TZM-bl cells [13]. 
These cells produce β-galactosidase in response to viral 
Tat, enabling the presence of HIV to be determined by 
the enzymatic cleavage of a luminescent compound. In 
contrast to TILDA the TZA assay utilises resting CD4+ 
T cells but also requires a significantly smaller blood vol-
ume than the standard VOA. Neither of these assays cor-
related closely with IUPM measured by a standard VOA 
implying that they may not measure the same component 
of the HIV reservoir. Another caveat is that as neither 
assay requires viral replication to detect reactivated virus, 
neither provides unequivocal proof that the detected 
viral products are derived from replication-competent 
virus.
Another novel technique that significantly shortens 
the assay time of the VOA, by use of an enhanced sen-
sitivity of p24 detection at ultra-low concentrations, 
has recently been applied to HIV latency research [14]. 
This ultrasensitive assay utilises Simoa single molecule 
automated array technology [15] which can measure 
sub-femtomolar concentrations of analytes using a 
micro-bead based antibody capture system. This promis-
ing method allows the detection and quantitation of p24 
produced by a single reactivated infected CD4+ T cell 
[14]. Although this method is very powerful in detecting 
viral protein production very early after reactivation, it is 
not yet clear if the measure represents replication-com-
petent virus and how it correlates to the VOA. There-
fore, the results of ongoing clinical studies like RIVER 
(Clinical trial registry identifier: NCT02336074) which 
employ both a VOA and the ultrasensitive p24 assay, 
among many other measures of the latent HIV reservoir, 
will be of tremendous interest in the search for a defini-
tive measure, or combination of measures, of the clini-
cally significant HIV reservoir.
As efforts to cure HIV progress it may become neces-
sary to be able to detect smaller reservoirs with greater 
confidence. A recent development on the VOA has been 
the development of the murine outgrowth system [16–
18]. It involves the injection of PBMCs or CD4 T cells 
into immunodeficient NSG mice [17, 18] or humanised 
mice [16]. These systems offer enhanced sensitivity as 
they are capable of sampling large number of cells. They 
can also give a semi-quantitative estimate of the reservoir 
size and outgrowth from patient cells where a standard 
VOA had been negative [16]. However, these assays are 
not easily scalable, limiting their deployment.
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Clinical utility
VOA is generally regarded as the gold standard in esti-
mating the size of the replication-competent latent viral 
reservoir. Interestingly in the REDUC trial [19], combi-
natorial application of a histone deacetylase inhibitor 
romidepsin, an HIV vaccine, and recombinant human 
GM-CSF has achieved a statistically significant reduction 
on the size of the latent reservoir as measured by total 
HIV DNA and by VOA in resting CD4 T cells, but not 
by integrated HIV DNA in total CD4 T cells. This illus-
trates the importance of including a range of outcome 
measures in clinical trials aimed at perturbing the latent 
reservoir until a definitive measure is identified. A num-
ber of other clinical studies have also included VOA as 
outcomes (Table 1). These studies represent only a frac-
tion of the cure effort and a recent survey [20] shows that 
VOA is being deployed in a only a minority (5 out of 25) 
of ongoing clinical trials on HIV cure. This highlights 
how the logistic difficulties outlined above and the asso-
ciated high costs limit the applicability of the assay.
Conclusions
Although there have been significant improvements in 
VOAs enhancing their applicability problems remain. 
Assays of the same patient performed in different labo-
ratories can yield different estimates of reservoir size, in 
part due to different experimental protocols. As yet there 
has been no international consensus on the optimum 
Fig. 1 a HIV infected SupT1-CCR5 cells form syncytia which can be readily discerned by microscopy. b The results of VOA using observed cyto-
pathic effect (CPE) as readouts strongly correlate with that using p24 ELISA
Page 4 of 6Norton et al. Retrovirology  (2017) 14:58 
protocol for measuring the latent reservoir, nor have 
there been efforts to standardise readouts using samples 
of known latent viral load. Addressing these issues will be 
essential to enable comparison of the results of clinical 
trials carried out at different centres. Additional limita-
tions of the VOA stem from the biology of HIV latency. 
Thus far, no method has been able to activate HIV in 
all latently infected cells, for which repeated rounds of 
reactivation may be necessary [21, 22]. It is not known 
whether the stimuli we have available are capable of reac-
tivating every provirus as our understanding of latency 
is incomplete and there is emerging evidence of a diver-
sity of mechanisms responsible for viral silencing [23]. 
Furthermore, cells carrying replication-competent latent 
HIV are so rare that large volume blood draws, or leu-
kapheresis, may remain a requisite for any VOA, adding 
to the logistic challenges of deploying and scaling up the 
assay. The pathophysiological importance of the param-
eter measured by VOA is the most compelling reason for 
it still to be considered a sine qua non of clinical trials of 
virus reactivation. However, as with all assays based on 
sampling of blood, it does not sample latently infected T 
cells in the tissue compartment. It is unclear if the latent 
T cells reservoir in the blood compartment fully recapit-
ulate that in the tissue compartment, as tissue resident T 
memory cells do not circulate [24]. Critically, there are as 
yet no robust data on how VOA correlates with the time 
to viral rebound after withdrawal of ART, which is ulti-
mately the clinically relevant outcome. It is sobering to 
note that the ‘Mississippi child’ had a undetectable latent 
viral load after cumulative sampling of 64 million resting 
CD4+ T cells [25] prior to rebound. Thus, whilst VOA 
is a powerful tool as it gives a physiologically relevant 
readout in clinical trials evaluating the efficacy of latency 
reversal, developing a simpler and cheaper but still repro-
ducible assay for the latent reservoir and establishing pre-
dictive parameters for clinical outcomes remain urgent 
research priorities.
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Table 1 Examples of clinical trials using VOA
IUPM infectious units per million cells as measured by VOA
Clinical trial no. Intervention Key finding References
NCT01319383 Vorinostat (single dose) 8 patients Single dose of vorinostat increased cell-associated RNA 
in resting CD4 cells but no reduction in IUPM
[26]
NCT01319383 Vorinostat (multiple doses 3 ×/week for 8 weeks) 5 
patients
Increase in cell-associated RNA with multiple doses 
compared to single dose of vorinostat in 3/5 
patients, no reduction in IUPM
[27]
NCT01319383 Vorinostat (multiple doses) 16 patients Multiple doses of vorinostat increased cell-associated 
RNA in resting CD4 cells but no reduction in IUPM
[28]
NCT01680094 Panobinostat 15 patients Increase in cell-associated RNA, increase in plasma 
viraemia, no significant reduction in total and inte-
grated DNA or IUPM. No delay in time to rebound 
in the 9 patients undergoing planned treatment 
interruption.
[29]
NCT00289952 Valproic acid and ART 56 patients No reduction in IUPM [30]
NCT01286259 Disulfiram 16 patients Transient increase in plasma viraemia in a subset of 
patients, no overall change in plasma viraemia in the 
entire cohort, no change in IUPM
[31]
NCT02443935 MGN1703 15 patients Significant reduction in cell-associated RNA post-treat-
ment, transient increase in plasma viraemia in 6/15 
patients. No change in total or integrated HIV DNA, 




Romidepsin, Vacc-4x and rhuGM-CSF 20 patients (17 
completed trial)
Significant decrease (40%) in total DNA (in 16 patients 
measurable), non-significant decrease (19%) in 
integrated DNA (15 patients measurable) significant 
reduction (38%) in IUPM (6 patients measurable). 
No delay in time to rebound in the 15 patients who 
have undergone post treatment interruption
[19]
NCT02336074 RIVER ART, Raltegravir, Vorinostat, ChAdV63.HIVconsv and 
MVA.HIVconsv
Ongoing
NCT02707900 VORVAX Vorinostat and AGS-004 Ongoing
NCT02471430
ACTIVATE
Panobinostat and Pegylated Interferon-alpha2a Ongoing
NCT02408861 Nivolumab and Ipilimumab Ongoing
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